Pasireotide

New to peptides? Start with what are peptides? and how do peptides work?

Overview

Pasireotide is a second-generation somatostatin analog, and the reason it exists is a specific limitation of the first generation. Octreotide and lanreotide bind mainly one somatostatin receptor subtype, SSTR2. That works well for growth-hormone-secreting pituitary tumors, which express SSTR2 abundantly. It works poorly for the ACTH-secreting pituitary tumors that cause Cushing's disease, which express mostly SSTR5.

Pasireotide was designed to close that gap. It binds four of the five receptor subtypes — SSTR1, 2, 3, and especially SSTR5 — with an affinity for SSTR5 many times higher than octreotide's. That broader reach is what allows it to suppress ACTH secretion at its source, something no other approved medical therapy for Cushing's disease does in quite the same way.

A drug defined by a trade-off

Broader receptor binding brings a cost, and with pasireotide it is unusually predictable: it raises blood sugar in a large majority of patients, often substantially. This is not an incidental side effect to be monitored in passing. It is a central, expected consequence of the drug's mechanism, it shapes who is offered the drug, and it frequently requires starting diabetes treatment alongside it.

Pasireotide is therefore best understood as a specialist option for difficult pituitary disease, where the alternative is uncontrolled cortisol or growth hormone excess — conditions with serious consequences of their own.

How it works

Broad receptor engagement

Somatostatin receptors come in five subtypes with different tissue distributions. Pasireotide binds SSTR1, SSTR2, SSTR3, and SSTR5, with its highest affinity at SSTR5. Compared with octreotide it is far more potent at SSTR5 and somewhat less potent at SSTR2. That inverted profile is the entire design rationale.

In Cushing's disease

Cushing's disease is caused by a pituitary tumor secreting excess ACTH, which drives the adrenal glands to overproduce cortisol. These corticotroph tumors are rich in SSTR5. By engaging SSTR5, pasireotide suppresses ACTH release directly from the tumor, lowering cortisol. Most other medical therapies for Cushing's work downstream — blocking cortisol synthesis in the adrenal gland or blocking the cortisol receptor in tissue. Pasireotide is one of the few that acts on the pituitary source itself.

In acromegaly

In acromegaly the target is growth hormone. Pasireotide's combined SSTR2 and SSTR5 activity lets it control growth hormone and IGF-1 in a proportion of patients who do not respond adequately to first-generation analogs, which is precisely the population it is positioned for.

Why it raises blood sugar

SSTR5 is heavily expressed on pancreatic beta cells and on the gut cells that release the incretin hormones GLP-1 and GIP. Strong SSTR5 activation therefore suppresses insulin secretion and blunts the incretin response to meals, while affecting glucagon comparatively less. The net result is reduced insulin availability at exactly the moment it is needed. This is a mechanistic certainty rather than an idiosyncratic reaction, which is why hyperglycemia is anticipated and managed proactively rather than simply watched for.

Clinical uses & evidence

Cushing's disease

Pasireotide was studied in patients with persistent or recurrent Cushing's disease after pituitary surgery, or in whom surgery was not an option. In randomized trials it produced sustained reductions in urinary free cortisol, with a meaningful minority of patients reaching normal levels, alongside improvements in blood pressure, weight, and clinical features of cortisol excess. Patients with more modest baseline cortisol elevation were more likely to reach full biochemical control — a useful predictor when selecting candidates.

Long-acting monthly formulations were subsequently studied and approved, offering the same benefit with a more practical schedule.

Acromegaly

In acromegaly, pasireotide was compared against octreotide and studied in patients inadequately controlled on first-generation analogs. It achieved biochemical control in a greater share of those inadequately controlled patients, establishing its role as a second-line option. Again, the trade-off was clear in the data: better hormone control, more hyperglycemia.

Reading the evidence honestly

Pasireotide's trials show real efficacy in populations with few good alternatives, and they show a consistent, quantified metabolic cost. Both halves matter. The drug is not a general-purpose upgrade to octreotide, and it is not positioned as one — it is a targeted answer to specific treatment failures, and the decision to use it is a genuine risk-benefit judgment made by a specialist.

Forms & how it's given

Pasireotide exists in two forms: a twice-daily subcutaneous injection, and a long-acting formulation injected into muscle roughly once a month. The choice depends on the indication and on how well the patient tolerates and responds to treatment.

Glucose monitoring is not optional. Standard practice includes assessing glucose status before starting, monitoring closely during the first months, and continuing periodically thereafter. Many patients require glucose-lowering therapy, and clinical guidance has emphasized agents that work through the incretin pathway, since that is the pathway pasireotide suppresses. Cortisol or growth hormone levels are tracked in parallel to titrate the dose.

We do not publish dosing protocols. Pasireotide is a specialist prescription medicine requiring coordinated endocrine and metabolic monitoring, and no consumer dosing exists or would be appropriate.

Safety & legal status

Hyperglycemia is the defining risk

The great majority of patients treated with pasireotide experience a rise in blood glucose, and a substantial share develop diabetes or require new or intensified glucose-lowering treatment. Severe hyperglycemia and diabetic ketoacidosis have been reported. This risk is disclosed prominently in the product labeling, and management of it is built into how the drug is prescribed.

Other effects

• Gastrointestinal effects — diarrhea, nausea, and abdominal pain, shared with the rest of the class.
• Gallstones and biliary sludge from reduced gallbladder emptying, requiring periodic imaging on long-term therapy.
• Bradycardia and QT prolongation, meaning electrocardiographic monitoring and caution with other QT-prolonging drugs.
• Liver enzyme elevations, monitored with periodic testing.
• Hypocortisolism — because the drug lowers cortisol deliberately, it can overshoot, producing fatigue, nausea, and low blood pressure that require dose reduction or replacement therapy.
• Injection-site reactions, particularly with the long-acting form.

Legal status

Pasireotide is an FDA-approved, prescription-only medicine used under close specialist supervision. It is not available outside the regulated supply chain and has no research-chemical market. Its risk profile is well characterized precisely because it went through formal clinical development — a contrast worth keeping in view when comparing it to unapproved compounds whose risks are simply unknown.

The somatostatin analogs compared

All three mimic somatostatin, the body's broad "off switch" hormone. What separates them is which receptor subtypes they reach — which in turn decides what each one can treat.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Pivonello R, De Leo M, Cozzolino A, et al. The Treatment of Cushing's Disease. Endocr Rev. 2015. Peer-reviewed study
2. Witek P, Bolanowski M, Krętowski A, et al. Pasireotide-induced hyperglycemia in Cushing's disease and Acromegaly: A clinical perspective and algorithms proposal. Front Endocrinol (Lausanne). 2024. Peer-reviewed study
3. McKeage K. Pasireotide in Acromegaly: A Review. Drugs. 2015. Peer-reviewed study
4. Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019. Peer-reviewed study